🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📢 #ESMOGROW is the 1⃣st #reporting guidance specifically for #RWEstudies in #oncology ‼️ out in Annals of Oncology and ESMO - Eur. Oncology Real World Data and Digital Oncology 🔝 teamwork led by Luis Castelo-Branco (MD; PharmD; PhD) 💫and supervised by Pr George Pentheroudakis, Dr Suzette Delaloge, and professor Miriam Koopman

ESMO-GROW is a guidance to homogenize reporting of Real World Data, in order to generate robust Real World Evidence. This includes general recommendations, how to report patient selection and recommendations about Data to include. Wide adoption will make RWD more impactful

Brainstorming on EnLiST, the ESMO - Eur. Oncology ESMO Adaptation of Lines of Systemic Therapy, with Chris Twelves, Kamal Saini, Miriam Koopman, Suzette Delaloze, the ESMO Real World Data Digital Working Group and individual experts from EMA FDA Industry EORTC CRO Patient Advocates

🔛 ESMO - Eur. Oncology webinar on #RWD & #DigitalOncology 🎙️moderated by Anna Pellat & Carola Schulz, ft. Franzoi Maria Alice, Danielle Seinstra, & Henrique Martins 💫 ✔️ #Oncology #RWD: challenges & opportunities ✔️ Needs in 1ary #data collection & sharing ✔️ 🇪🇺 Electronic #HealthRecord Format

In this study Sally Yaacoub and colleagues examine the characteristics of comparative non-randomised studies that assess the effectiveness or safety, or both, of drug treatments. Read the full research article here: bit.ly/4hsgGfu Anna Pellat Viet-Thi Tran @IsabelleBoutron